THE NEW
FRONTIER IN
OPHTHALMIC CARE
.
VISION
Transforming
Anterior Segment
Disease Management, from Glaucoma to Beyond
Smartlens is redefining anterior segment disease management through breakthrough technologies that address critical unmet needs in continuous monitoring, diagnosis, and treatment optimization. Our flagship platform focuses on intraocular pressure (IOP) - the primary risk factor for glaucoma, the leading cause of irreversible blindness worldwide. By combining novel microfluidic technology with AI-enhanced diagnostics, we enable precise, real-time tracking and personalized care management. Our integrated solution represents a paradigm shift in ophthalmic care, moving from episodic office visits to continuous, data-driven treatment across multiple anterior segment conditions. By fundamentally transforming how these diseases are monitored and treated, Smartlens enables early detection, improved outcomes, and broader access to specialist care.
PORTFOLIO
Redefining Care for Anterior Segment Diseases
miLens™ (in U.S. pivotal trials)
Current glaucoma management relies on infrequent IOP measurements during office visits, missing critical pressure variations that can lead to irreversible vision loss. Our flagship product miLens is a breakthrough, non-invasive device that enables remote monitoring of intraocular pressure (IOP) anywhere, at any time through a comfortable, electronics-free contact lens design. Designed for diurnal monitoring, it's the world's smallest wearable microfluidic device and works seamlessly with our AI-powered smartphone-based imaging system. miLens captures critical pressure variations missed by current quarterly or annual measurements, enabling early detection of dangerous IOP spikes for timely intervention. With strong clinical validation, patent-protected technology, and 96.2% of practitioners indicating adoption intent, miLens™ is poised to transform glaucoma management through its ultra-sensitive technology.
Slit IQ™ (in US pivotal trials)
AI-powered remote examination platform that brings specialist-level eye care to any smartphone. Our proprietary imaging system enables comprehensive anterior segment exams with clinical-grade standardization. 50% of all eye care visits can potentially be performed through Slit IQ™, facilitating telemedicine capabilities and standardizing disease assessment through AI-enhanced documentation. The platform provides consistent monitoring of multiple conditions including corneal and conjunctival diseases, cataracts, anterior uveitis, and trauma. By expanding specialist access across geographical barriers and reducing unnecessary in-person visits, Slit IQ™ enables more efficient, accessible, and standardized eye care delivery.
THERx IQ™ (in pilot trials)
A novel wearable device that addresses poor medication adherence and imprecise dosing in chronic eye diseases. The automated system delivers personalized micro-dose medications, with initial focus on glaucoma treatment based on actual diurnal IOP data. Its unique micro-dosing technology enhances therapeutic efficacy while minimizing side effects common with traditional eye drops. The programmable platform optimizes treatment timing based on each patient's pressure patterns and can deliver single or multiple medications precisely when needed. Designed for versatility across chronic eye conditions, THERx IQ™'s automated approach removes patient compliance barriers while ensuring optimal drug delivery, potentially reducing disease progression through consistent medication management.
miLens IQ+™
AI/ML-powered platform unlocking insights from first-of-its-kind diurnal IOP monitoring and comprehensive imaging data. By integrating intraocular pressure patterns from miLens™ and standardized anterior segment imaging from Slit IQ™, the system provides deeper understanding of disease progression across multiple conditions. The platform eliminates subjective variability through standardized, quantifiable measurements of both pressure data and structural changes. Integrating seamlessly with our monitoring technologies, it provides real-time risk stratification and data-driven analysis to inform treatment decisions across anterior segment diseases. The platform's predictive capabilities, enhanced by intraocular pressure monitoring and imaging analysis, enable early intervention by identifying high-risk patients before significant disease progression.
Glacouma In Numbers
56%
Undiagnosed
Population in the US
38%
Of Patients Have Irreversible Blindness in EU
20%
Are At Severe Stage
(High Risk Of Blindness)
>140million
People are suffering from Glaucoma worldwide